Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1907-1914

  Kang, Kyoung Ah ^a   Piao, Mei Jing ^a   Kim, Ki Cheon ^a   Zheng, Jian ^a   Yao, Cheng Wen ^a   Cha, Ji Won ^a   Kim, Hye Sun ^b   Kim, Dong Hyun ^c   Bae, Suk Chul ^d   Hyun, Jin Won ^a  

^a Jeju National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

^d Chungbuk National University   (South Korea)

Author keywords

Compound K; Histone deacetylase; Runt related transcription factor

Indexed keywords

COMPOUND K; DNA; DRUG METABOLITE; GINSENG SAPONIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX3; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; PANAX; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER;

EID: 84891942804     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2129     Document Type: Article

References (55)

1. Kouzarides T: Chromatin modifications and their function. Cell 128: 693-705, 2007.
2. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
3. Gallinari P, Di Marco S, Jones P, Pallaoro M and Steinkühler C: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17: 195-211, 2007.
4. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH and Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558, 2006.
5. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M and Tsuneyoshi M: Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18: 769-774, 2007.
6. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S and Kimura W: Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 60: 1205-1210, 2007.
7. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Göttlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463, 2004.
8. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC and Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21(Cip1/WAF1) expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404, 2005.
9. Giannini R and Cavallini A: Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res 25: 4287-4292, 2005.
10. Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14: 1669-1677, 2008.
11. Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M and Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008.
12. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137-147, 2007.
13. WAF-1 is required for butyrate-mediated growth inhibition of colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
14. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R and Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193, 1999.
15. Myzak MC and Dashwood RH: Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide and sulforaphane. Curr Drug Targets 7: 443-445, 2006.
16. Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT and Ryningen A: Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr Pharm Biotechnol 8: 388-400, 2007.
17. Levanon D, Brenner O, Negreanu V, Bettoun D, Woolf E, Eilam R, Lotem J, Gat U, Otto F, Speck N and Groner Y: Spatial and temporal expression pattern of Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse embryogenesis. Mech Dev 109: 413-417, 2001.
18. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, Levanon D and Groner Y: Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 100: 7731-7736, 2003.
19. Choi JK, Lee YH, Kim HM, Li LS, Kim H, Chang J, Ito Y, Lee KY and Bae SC: Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314: 223-228, 2004.
20. Chuang LS and Ito Y: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29: 2605-2615, 2010.
21. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V and Ingvarsson S: Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79: 1468-1474, 1999.
22. Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T and Miyaki M: Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 8: 2253-2258, 1993.
23. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
24. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue Ki, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002.
25. Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR: Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 112: 754-759, 2004.
26. Fujii S, Ito K, Ito Y and Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
27. Lee SH, Kim J, Kim WH and Lee YM: Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28: 184-194, 2009.
28. Hong SY, Cho JY and Seo DW: Ginsenoside Rp1 inhibits proliferation and migration of human lung cancer cells. Biomole Ther 19: 411-418, 2011.
29. Park JW, Lee JC, Ann S, Seo DW, Choi WS, Yoo YH, Park SK, Choi JY, Um SH, Ahn SH and Han JW: A fermented ginseng extract, BST204, inhibits proliferation and motility of human colon cancer cells. Biomole Ther 19: 211-217, 2011.
30. Seo EY and Kim WK: Red ginseng extract reduced metastasis of colon cancer cells in vitro and in vivo. J Gins Res 35: 315-324, 2011.
31. Akao T, Kanaoka M and Kobashi K: Appearance of Compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of Compound K by enzyme immunoassay. Biol Pharm Bull 21: 245-249, 1998.
32. Hasegawa H, Sung JH and Huh JH: Ginseng intestinal bacterial metabolite IH901 as a new anti-metastatic agent. Arch Pharm Res 20: 539-544, 1997.
33. Quan LH, Cheng LQ, Kim HB, Kim JH, Son NR, Kim SY, Jin HO and Yang DC: Bioconversion of Ginsenoside Rd into Compound K by Lactobacillus pentosus DC101 isolated from Kimchi. J Gins Res 34: 288-295, 2010.
34. Kang KA, Kim YW, Kim SU, Chae S, Koh YS, Kim HS, Choo MK, Kim DH and Hyun JW: G1 phase arrest of the cell cycle by a ginseng metabolite, Compound K, in U937 human monocytic leukamia cells. Arch Pharm Res 28: 685-690, 2005.
35. Kang KA, Lim HK, Kim SU, Kim YW, Kim WT, Chung HS, Choo MK, Kim DH, Kim HS, Shim MJ, Chung MH and Hyun JW: Induction of apoptosis by ginseng saponin metabolite in U937 human monocytic leukemia cells. J Food Biochem 29: 27-40, 2005.
36. Chae S, Kang KA, Chang WY, Kim MJ, Lee SJ, Lee YS, Kim HS, Kim DH and Hyun JW: Effect of Compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem 57: 5777-5782, 2009.
37. Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH, Jeon YJ, Lee CH, Park J, Chang WY and Hyun JW: Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol 30: 134-140, 2010.
38. Kang KA, Kim HS, Kim DH and Hyun JW: The role of a ginseng saponin metabolite as a DNA methyltransferase inhibitor in colorectal cancer cells. Int J Oncol 43: 228-236, 2013.
39. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H and Ito Y: RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237, 2008.
40. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004.
41. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC and Ito Y: The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26: 4474-4488, 2006.
42. Tong DD, Jiang Y, Li M, Kong D, Meng XN, Zhao YZ, Jin Y, Bai J, Fu SB and Geng JS: RUNX3 inhibits cell proliferation and induces apoptosis by TGF-beta-dependent and -independent mechanisms in human colon carcinoma cells. Pathobiology 76: 163-169, 2009.
43. Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, Hommes DW, Offerhaus GJ, van den Brink GR and Hardwick JC: The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31: 1567-1575, 2010.
44. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
45. Jones PA: DNA methylation and cancer. Oncogene 21: 5358-5360, 2002.
46. Counts JL and Goodman JI: Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83: 13-15, 1995.
47. Shibata S: Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 16: S28-S37, 2001.
48. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I and Lee P: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1: 62-71, 2009.
49. Patra SK, Patra A and Dahiya R: Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287: 705-713, 2001.
50. Halkidou K, Gaughan L, Cook S, Leung HY, Neal D and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189, 2004.
51. Yang XJ and Seto E: Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 13: 143-153, 2003.
52. Kim DH, Kim M and Kwon HJ: Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36: 110-119, 2003.
53. Buchwald M, Krämer OH and Heinzel T: HDACi - targets beyond chromatin. Cancer Lett 280: 160-167, 2009.
54. Mellert HS, Stanek TJ, Sykes SM, Rauscher FJ III, Schultz DC and McMahon SB: Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis. J Biol Chem 286: 4264-4270, 2011.
55. Oh ET, Park MT, Choi BH, Ro S, Choi EK, Jeong SY and Park HJ: Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs 30: 435-442, 2012.